SINPAIN Results: New Insights and Approaches for Osteoarthritis Research

Understanding the connection between inflammation and pain

One of SINPAIN's key achievements has been to improve our understanding of the cellular mechanisms involved in osteoarthritis.

Using advanced technologies to analyse individual cells and their interactions within joint tissue, researchers identified specific cell populations involved in both inflammation and pain. Their findings revealed that several types of cells produce two important biological factors: interleukin-1 beta (IL-1β), which contributes to inflammation, and nerve growth factor (NGF), which is associated with pain.

The research also identified increased communication between cells associated with blood vessels in affected joint tissue, providing further insights into the complex interactions involved in the disease.

These findings helped inform the development of therapeutic approaches designed to address multiple sources of inflammation and pain rather than targeting a single cell population.

Developing new approaches to target inflammation and pain

Building on these findings, SINPAIN researchers developed innovative nanotherapeutic approaches designed to interfere with the biological processes contributing to osteoarthritis.

One approach uses small interfering RNA (siRNA), a technology that can reduce the production of specific proteins. Researchers identified lipid nanoparticle formulations capable of delivering siRNA to reduce the expression of IL-1β and NGF, two factors associated with inflammation and pain.

Another development is an injectable hydrogel designed to deliver therapeutic agents directly into the knee joint, with the aim of controlling inflammation and reducing pain.

These approaches represent important steps in exploring new treatment strategies that target the mechanisms underlying osteoarthritis. Further research is needed to evaluate their potential for clinical application.

Creating more realistic models to evaluate new therapies

To investigate how potential treatments behave in the complex environment of an osteoarthritic joint, SINPAIN developed advanced three-dimensional human cell models.

These models combine different types of joint cells and reproduce important aspects of the joint environment, including inflammatory conditions and mechanical forces experienced during movement. Following extensive optimisation, the models generated stable and reproducible biological responses, enabling researchers to evaluate nanotherapeutic approaches under controlled, human-relevant conditions.

SINPAIN also established a clinically relevant rabbit model to study early osteoarthritis progression and evaluate new therapeutic approaches. The model allows researchers to examine changes in cartilage and surrounding joint tissues and investigate how potential treatments behave in an affected joint.

Together, these complementary models provide valuable tools for preclinical research, helping to bridge the gap between laboratory findings and future clinical studies.

Improving osteoarthritis assessment through imaging and AI

SINPAIN has also developed new methods to assess osteoarthritis and better characterise differences between patients.

By combining magnetic resonance imaging (MRI) and computed tomography (CT), researchers developed an approach that integrates information about cartilage, other soft tissues and bone. Artificial intelligence (AI) supports the analysis of these complex datasets, helping to identify relevant features for assessing cartilage degeneration.

This work contributes to making osteoarthritis assessment more objective and could, in the future, support more personalised treatment decisions.

Alongside these imaging advances, the project has contributed to a better understanding of osteoarthritis progression, providing a basis for further research into earlier disease detection and assessment.

Building a foundation for future osteoarthritis treatments

SINPAIN's results demonstrate the importance of connecting different areas of research to address the complexity of osteoarthritis. By combining insights into the cellular mechanisms of inflammation and pain with the development of targeted nanotherapies, advanced disease models and improved assessment methods, the project has contributed to several important areas of osteoarthritis research.

Alongside these scientific advances, SINPAIN also addressed regulatory considerations relevant to the future development of innovative therapies. Understanding requirements related to product classification, quality, safety and the evidence needed for further development is essential for planning the steps towards potential clinical application.

The project developed an early regulatory roadmap, strengthened regulatory awareness across the consortium and engaged with European regulatory experts through a meeting with the European Medicines Agency's (EMA) Innovation Task Force. The exchange provided early feedback on key quality and non-clinical questions, helping inform future development strategies.

Exchanges with patient representatives also reinforced the importance of addressing the everyday challenges faced by people living with osteoarthritis.

While further research and validation will be needed to assess whether these advances can be translated into clinical practice, SINPAIN has established scientific knowledge, innovative technologies, research tools and a stronger understanding of regulatory requirements that can support future osteoarthritis research and therapeutic development.

Explore the SINPAIN results

Discover the research behind these developments in our SINPAIN Results series, where researchers explain the project's scientific achievements, challenges and future perspectives.